gurbert
Recently Joined
🚫No Source Discussion🚫
I’m compiling preclinical (lab rat) observations on Selank and Semax, and would really value input from researchers/experienced testers.
I’m specifically interested in:
My current log: my rat is on day 3 of SubQ Selank, started at ~10 units from a 3 mL / 10 mg (~330mcg) vial, and I plan to increase toward about 500 mcg until the 10 mg is finished (Depending how it goes I might keep going up if I decide to stay with SubQ). Then I’ll switch to intranasal and compare route differences. I’ll report back incrementally. Not sure if my rat will try Semax though.
Thanks in advance to anyone willing to share protocols, pitfalls, or negative results too.
My current Theory
Here's some interesting rat data, however the studies are intraperitoneal (IP) Semax/Selank (NOT subQ) and intranasal.
Semax
Russian studies:
I’m specifically interested in:
- Route comparison: SubQ vs intranasal
- Compound strategy: Semax alone, Selank alone, vs combined (co-administered)
- Outcomes: behavioral/cognitive/anxiety-like effects, and any clear CNS-signaling differences
- Practicals: dose range, frequency, timing, washout, and whether route changed effect consistency
- Tolerability/signals: local irritation, stress response, habituation/tachyphylaxis, etc.
- Strain/sex/age (useful but not necessary if your rat is shy)
- Dosing protocol (mcg, schedule, duration)
- Route and formulation
- Whether combo was simultaneous or staggered
My current log: my rat is on day 3 of SubQ Selank, started at ~10 units from a 3 mL / 10 mg (~330mcg) vial, and I plan to increase toward about 500 mcg until the 10 mg is finished (Depending how it goes I might keep going up if I decide to stay with SubQ). Then I’ll switch to intranasal and compare route differences. I’ll report back incrementally. Not sure if my rat will try Semax though.
Thanks in advance to anyone willing to share protocols, pitfalls, or negative results too.
My current Theory
Route-to-Phenotype Hypothesis (Selank)
Intranasal and SubQ may not be interchangeable; they may produce different anxiolytic phenotypes.
SubQ Research Positioning
- Panic / acute surges: likely favor intranasal due to faster CNS-onset effects (strongest in the ~30-180 min window).
- Baseline generalized anxiety / chronic nervousness / work-stress reactivity: may favor SubQ because steadier exposure could reduce symptom fluctuation over days to weeks.
- Performance anxiety: depends on timing goals: intranasal for immediate pre-stressor effect, SubQ for all-day baseline smoothing.
SubQ should be studied as a distinct therapeutic profile, not a replacement route:
- slower onset,
- potentially steadier background anxiolysis,
- possibly better for baseline stress tone than rapid interruption of acute spikes.
Here's some interesting rat data, however the studies are intraperitoneal (IP) Semax/Selank (NOT subQ) and intranasal.
Semax
Semax (rats): IP vs Intranasal
Selank (rats): IP vs Intranasal
- Intranasal: Best evidence for direct CNS-linked effects (neurotrophic/signaling and behavioral readouts).
- IP: Strong systemic neuroprotection/anti-inflammatory effects in injury models; still reaches brain effects, but via systemic exposure.
- Practical difference: Intranasal is usually chosen for brain-targeted peptide delivery logic; IP is easier for controlled systemic dosing in lab protocols.
Bottom line
- Intranasal: Clear anxiolytic/stress-modulating behavioral evidence.
- IP: Also shows anti-stress/withdrawal-related effects, but route is systemic and not directly equivalent to nose-to-brain assumptions.
- Practical difference: Intranasal is more aligned with CNS-focused peptide use; IP is common for reproducible systemic administration.
- For both Semax and Selank, rat literature supports activity by both routes.
- The main gap is few true head-to-head IP vs intranasal comparisons in the same study, so cross-paper comparisons are directional, not definitive.
Russian studies:
References:As of February 17, 2026, the human dosing reported in Russian clinical use/trials is roughly:
- Semax 0.1% intranasal (non-stroke indications):
- Common ranges in label/clinical practice: about 400–900 mcg/day (fatigue/adaptation) and higher in cerebrovascular settings.
- Label also lists cerebrovascular cognitive regimens up to 800–8000 mcg/day for 10–14 days.
- Source: https://www.vidal.ru/drugs/semax__28676
- Semax 1% intranasal (acute ischemic stroke protocols):
- Moderate stroke: about 6000–12,000 mcg/day
- Severe stroke: about 12,000–20,000 mcg/day
- Typical course: 10 days
- Source: https://www.vidal.ru/drugs/semax__37577
- Selank intranasal (human anxiety study data):
- Reported dose: 2700 mcg/day intranasal (GAD study abstract; response tracked over ~14 days, some reports up to 21 days).
- Source: https://www.cambridge.org/core/jour...lytic-selank/7A497218D37084BD079EFE143126F56E
- Selank label-style intranasal regimen often cited:
- 2 drops per nostril, 3x/day, 14 days (with repeat after break)
- Source (instruction mirror): https://extrapharma.net/instructions/selank-nasal-drops-instructions/
Semax
- Intranasal
- Intraperitoneal (IP) / systemic injection models
Selank
- https://pubmed.ncbi.nlm.nih.gov/34201112/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC8226508/
- https://pubmed.ncbi.nlm.nih.gov/32580520/
- https://pubmed.ncbi.nlm.nih.gov/33263853/
- Intranasal
- Intraperitoneal (IP) / systemic injection models
Last edited: